ARQT vs. ADMA

Last updated Apr 2, 2026

Compare and contrast key facts about Arcutis Biotherapeutics, Inc. (ARQT) and ADMA Biologics, Inc. (ADMA).

Performance

ARQT vs. ADMA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Arcutis Biotherapeutics, Inc. (ARQT) and ADMA Biologics, Inc. (ADMA). The values are adjusted to include any dividend payments, if applicable.

ARQT vs. ADMA - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020
ARQT Arcutis Biotherapeutics, Inc.	-17.01%	108.47%	331.27%	-78.18%	-28.64%	-26.27%	29.04%
ADMA ADMA Biologics, Inc.	-50.05%	6.36%	279.42%	16.49%	175.18%	-27.69%	-50.76%

Fundamentals

Market Cap ARQT : $3.27B ADMA : $2.22B
EPS ARQT : -$0.12 ADMA : $0.60
PS Ratio ARQT : 8.45 ADMA : 4.39
PB Ratio ARQT : 17.25 ADMA : 4.65
Total Revenue (TTM) ARQT : $376.07M ADMA : $510.17M
Gross Profit (TTM) ARQT : $339.38M ADMA : $292.77M
EBITDA (TTM) ARQT : -$1.11M ADMA : $195.35M

Returns By Period

In the year-to-date period, ARQT achieves a -17.01% return, which is significantly higher than ADMA's -50.05% return.

ARQT

• 1D: 2.29%
• 1M: -2.67%
• YTD: -17.01%
• 6M: 21.96%
• 1Y: 60.88%
• 3Y*: 29.88%
• 5Y*: -4.12%
• 10Y*: —

ADMA

• 1D: 1.11%
• 1M: -45.05%
• YTD: -50.05%
• 6M: -39.47%
• 1Y: -53.09%
• 3Y*: 40.14%
• 5Y*: 37.85%
• 10Y*: 0.79%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

ARQT vs. ADMA — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

ARQT

ARQT Risk / Return Rank: 72
ARQT Sharpe Ratio Rank: 74
ARQT Sortino Ratio Rank: 74
ARQT Omega Ratio Rank: 69
ARQT Calmar Ratio Rank: 72
ARQT Martin Ratio Rank: 72

ADMA

ADMA Risk / Return Rank: 7
ADMA Sharpe Ratio Rank: 5
ADMA Sortino Ratio Rank: 7
ADMA Omega Ratio Rank: 8
ADMA Calmar Ratio Rank: 11
ADMA Martin Ratio Rank: 3

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

ARQT vs. ADMA - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Arcutis Biotherapeutics, Inc. (ARQT) and ADMA Biologics, Inc. (ADMA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	ARQT	ADMA	Difference
Sharpe ratio Return per unit of total volatility	1.02	-0.93	+1.95
Sortino ratio Return per unit of downside risk	1.85	-1.32	+3.16
Omega ratio Gain probability vs. loss probability	1.22	0.83	+0.38
Calmar ratio Return relative to maximum drawdown	1.69	-0.82	+2.51
Martin ratio Return relative to average drawdown	3.97	-1.80	+5.76
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

ARQT vs. ADMA - Sharpe Ratio Comparison

The current ARQT Sharpe Ratio is 1.02, which is higher than the ADMA Sharpe Ratio of -0.93. The chart below compares the historical Sharpe Ratios of ARQT and ADMA, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	ARQT	ADMA	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	1.02	-0.93	+1.95
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.06	0.63	-0.69
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	0.01	—
Sharpe Ratio (All Time) Calculated using the full available price history	0.02	0.01	+0.01

Correlation

The correlation between ARQT and ADMA is 0.27, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

ARQT vs. ADMA - Dividend Comparison

Neither ARQT nor ADMA has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

ARQT vs. ADMA - Drawdown Comparison

The maximum ARQT drawdown since its inception was -95.02%, roughly equal to the maximum ADMA drawdown of -91.28%. Use the drawdown chart below to compare losses from any high point for ARQT and ADMA.

Drawdown Indicators

	ARQT	ADMA	Difference
Max Drawdown Largest peak-to-trough decline	-95.02%	-91.28%	-3.74%
Max Drawdown (1Y) Largest decline over 1 year	-31.99%	-66.18%	+34.19%
Max Drawdown (5Y) Largest decline over 5 years	-94.71%	-66.18%	-28.53%
Max Drawdown (10Y) Largest decline over 10 years	—	-87.33%	—
Current Drawdown Current decline from peak	-34.83%	-62.83%	+28.00%
Average Drawdown Average peak-to-trough decline	-50.46%	-52.92%	+2.46%
Ulcer Index Depth and duration of drawdowns from previous peaks	13.63%	30.12%	-16.49%

Volatility

ARQT vs. ADMA - Volatility Comparison

The current volatility for Arcutis Biotherapeutics, Inc. (ARQT) is 15.32%, while ADMA Biologics, Inc. (ADMA) has a volatility of 32.15%. This indicates that ARQT experiences smaller price fluctuations and is considered to be less risky than ADMA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	ARQT	ADMA	Difference
Volatility (1M) Calculated over the trailing 1-month period	15.32%	32.15%	-16.83%
Volatility (6M) Calculated over the trailing 6-month period	43.81%	44.57%	-0.76%
Volatility (1Y) Calculated over the trailing 1-year period	60.16%	57.46%	+2.70%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	71.95%	59.98%	+11.97%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	77.53%	69.11%	+8.42%

Financials

ARQT vs. ADMA - Profitability Comparison

The chart below illustrates the profitability comparison between Arcutis Biotherapeutics, Inc. and ADMA Biologics, Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

ARQT - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Arcutis Biotherapeutics, Inc. reported a gross profit of 117.82M and revenue of 129.50M. Therefore, the gross margin over that period was 91.0%.

ADMA - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, ADMA Biologics, Inc. reported a gross profit of 88.82M and revenue of 139.16M. Therefore, the gross margin over that period was 63.8%.

ARQT - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Arcutis Biotherapeutics, Inc. reported an operating income of 18.39M and revenue of 129.50M, resulting in an operating margin of 14.2%.

ADMA - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, ADMA Biologics, Inc. reported an operating income of 62.75M and revenue of 139.16M, resulting in an operating margin of 45.1%.

ARQT - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Arcutis Biotherapeutics, Inc. reported a net income of 17.40M and revenue of 129.50M, resulting in a net margin of 13.4%.

ADMA - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, ADMA Biologics, Inc. reported a net income of 49.38M and revenue of 139.16M, resulting in a net margin of 35.5%.